INTRODUCTION
The resistance to the drug over time limits the effi cacy of paclitaxel in anticancer therapy (McGrogan et al., 2008) , although paclitaxel is an antineoplastic agent with proven effi cacy in the treatment of breast, ovarian, lung, and colon cancers (Haldar et al., 1996; Lee et al., 1997) . The mechanisms by which cancer cells become multidrug resistant is thought to be correlated predominantly with the overexpression of Pglycoprotein effl ux pump (Callaghan and Higgins, 1995; Yusa and Tsuruo, 1989; Gottesman, 2002) . Thus, the development of compounds that block P-glycoprotein-mediated effl ux has been the conventional approach used to overcome multidrugresistance (MDR) (Wu et al., 2008) . However, the exact mechanisms responsible for the increase in P-glycoprotein levels following chemotherapeutic therapy remain to be established. Selective expression of protein kinase C isozymes has been known to be correlated with MDR (Blobe et al., 1993; Gupta et al., 1996) . Other works have revealed a link between sphingomyelinase activity and MDR (Jaffrezou et al., 1991) . On the other hand, the available data on the role of Raf-1 in paclitaxExperiments were carried out to determine the role of Raf-1 kinase in the development of drug resistance to paclitaxel in v-H-ras transformed NIH 3T3 fi broblasts (Ras-NIH 3T3). We established a multidrug-resistant cell line (Ras-NIH 3T3/Mdr) from Ras-NIH 3T3 cells by stepwise increases in paclitaxel. Drug sensitivity assays indicated that the IC 50 value for drug-resistant Ras-NIH 3T3/Mdr cells was more than 1 μM paclitaxel, 10-or more-fold higher than for the parental Ras-NIH 3T3 cells. Western blot and RT-PCR analysis showed that the drug effl ux pump a P-glycoprotein were highly expressed in Ras-NIH 3T3/Mdr cells, while not being detectable in Ras-NIH 3T3 cells. Additionally, verapamil, which appears to inhibit drug effl ux by acting as a substrate for P-glycoprotein, completely reversed resistance to paclitaxel in Ras-NIH 3T3/Mdr cell line, indicating that resistance to paclitaxel is associated with overexpression of the multidrug resistance gene. Interestingly, Ras-NIH 3T3/Mdr cells have higher basal Raf-1 activity compared to Ras-NIH 3T3 cells. Unexpectedly, however, the colocalization of Raf-1 and its negative regulator Spry2 was less observed in cytoplasm of Ras-NIH 3T3/Mdr cells due to translocation of Spry2 around the nucleus in the perinuclear zone, implying that Raf-1 may be released from negative feedback inhibition by interacting with Spry2. We also showed that shRNAmediated knockdown of Raf-1 caused a moderate increase in cell susceptibility to paclitaxel. Thus, the results presented here suggest that a Raf-1-dependent pathway plays an important role in the development of acquired drug-resistance.
el-induced acquired drug-resistance are still controversial, although previous researches have indicated that Raf-1 overexpression might be related to the MDR development in human cancer cell lines in vitro (Weinstein-Oppenheimer et al., 2001; Davis et al., 2003; Dong et al., 2009) Raf-1, a cytoplasmic serine/threonine protein kinase, is activated by an interaction with Ras-GTP, which recruits Raf-1 to the plasma membrane and induces a conformation change that relieves an inhibition imposed by the N terminus on the catalytic domain (Marshall, 1995) . Regarding the mechanism responsible for Raf-1 inactivation, Yeung and colleagues identifi ed the suppressing effect of the Raf-1 kinase inhibitory protein (RKIP) on the activation status of the Raf-1/MEK/ ERK pathways (Yeung et al., 1999) . RKIP involvement in the reversal of tumor cell resistance to chemotherapeutic agents has also been reported previously Jazirehi et al., 2004) . Other more potent inhibitor of the Raf-1 kinase activation is the Sprouty (Yusoff et al., 2002; Sasaki et al., 2003) , which was fi rst identifi ed in a genetic screen in Drosophila (Hacohen et al., 1998) . Our previous reports suggested that the enhancement of Raf-1 kinase activity by Spry2
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The present research was performed to investigate the correlation of Raf-1 kinase activity with the MDR development of Ras-NIH 3T3 cells. Our fi ndings suggest that the enhancement of Raf-1 kinase activity, which occurs in parallel with the decrease in the interaction with Spry2, may contribute to the development of acquired resistance in Ras-NIH 3T3 cells. Furthermore, we explored the reversal effect of Raf-1 shRNA transfection on the multidrug resistance, with the aim of gaining a promising therapy to reverse the tumor MDR effi ciently.
MATERIALS AND METHODS

Antibodies and reagents
Mouse monoclonal anti-Raf (E-10), polyclonal anti-ERK, and anti-Bcl-2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), while anti-cleaved PARP, anti-phospho-MEK (Ser217/221), and anti-phospho-ERK (Thr202/Tyr204) were from Cell Signaling Technology (Denvers, MA). A polyclonal anti-spry2 was purchased from Millipore Co. (Billerca, MA). Protein A-agarose was from Roche Molecular Biochemicals (Indianapolis, IN). Dulbecco's modifi ed Eagle's medium (DMEM), fetal calf serum and penicillin-streptomycin were purchased from GIBCO-Invitrogen (Carlsbad, CA). Reagents for SDS-polyacrylamide gel electrophoresis were from BioRad (Hercules, CA). Paclitaxel and verapamil were obtained from Sigma (St. Louis, MO).
Mammalian cell culture, transient transfection and chemical treatment
Ras-NIH 3T3 cells, which show morphologically transformed foci of cells with the characteristics of crisscrossed margins, piling up properties and invasiveness , were maintained at 37 o C in DMEM supplemented with 10% FCS, penicillin-streptomycin, and glutamine. For experimental purposes, cells were cultured in 60-mm tissue culture dishes until they reached −80% confl uency. For Raf-1 knockdowns, short hairpin RNA (shRNA) constructs against Raf-1 (catalog number TR516793) were purchased from OriGene Technologies, Inc. (Rockville, MD, USA). The targeted sequences were: TGTGACATCTGTCAGAAGTTCCTGCTAAA (TI593078). Raf-1 shRNA was transfected into cells using Lipofectamine 2000 (Invitrogen) in Opti-minimal essential medium I medium (Invitrogen) according to the manufacturer's protocol. After 24 h, the transfected cells were treated with chemical. Paclitaxel was dissolved in DMSO and freshly diluted for each experiment. DMSO concentrations were less than 0.1% in all experiment.
Establishment of paclitaxel-resistant v-H-ras-transformed cell line
Paclitaxel-resistant Ras-NIH 3T3/Mdr cells were derived from Ras-NIH 3T3 cells by stepwise increased concentrations of paclitaxel. Briefl y, paclitaxel was fi rst added to the parental Ras-NIH 3T3 cells to a fi nal concentration of 100 nM, and the cells were incubated at 37 o C for 2 days. Then the medium was changed to fresh one without paclitaxel and cells were cultured until the cells were again almost 80% confl uent. The concentration of paclitaxel was then increased by 50 nM increments until a concentration of 800 nM was reached. This cyclic treatment was repeated over a period of 18 weeks. The new Ras-NIH 3T3/Mdr cell line that grew at the maximum concentration of paclitaxel was stored for further analyses. For maintenance of paclitaxel-resistant cells, 100 nM paclitaxel was added into the normal medium. Before experimental use, Ras-NIH 3T3/Mdr cells were maintained in a paclitaxel-free culture medium and subcultured at least three times.
Cell growth assay
The cell proliferation reagent WST-1 was used for the quantitative determination of cellular proliferation and activation (Roche Molecular Biochemicals, Germany). For proliferation assays, the cells were plated in quadruplicates into 96-well microliter plates (Costar, Cambridge, MA) at 5×10 3 cells/ well and then treated with paclitaxel at 37 o C in a humidifi ed 5% CO2/95% air incubator. After incubation for 2 or 3 days, the cells were incubated for additional 4 h in the presence of WST-1 labeling mixture (10 μl per well). The absorbance of the samples against a background control (medium alone) as a blank was measured at 450 nm using a microliter plate (ELISA) reader (Molecular Devices, Sunnyvale. CA).
RNA extraction and RT-PCR
Twenty-four hours after plating of 1×10 6 Ras-NIH 3T3 or Ras-NIH 3T3/Mdr cells, total RNA was purifi ed with RNeasy mini kit (QIAGEN, Valencia, CA). Complementary DNA (cDNA) was made by reverse-transcription (RT) of 1 μg each total RNA using OneStep RT-PCR Kit (QIAGEN). The primer sets were 5′-tgcttatggatcccagagtgac-3′ and 5′-ttggtgaggatctctccggct-3′ for mdr1; 5′-agtgaaaggggctacagggt-3′ and 5′-aacttctgctcccgagtcaa-3′ for mdr3. Each of the amplifi ed PCR products was determined by electrophoresis on an 1.5% agarose gel.
Preparation of cell lysates and immunoblot analysis
The treatments of cells were carried out at 37 o C in serumfree medium as described in the fi gure legends. Following treatment, whole cell lysates were prepared as follows. Cells were washed twice with ice-cold phosphate-buffered saline (PBS), and harvested by scraping the cells into lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM phenylmethylsulfonyl fl uoride, 20 μg/ml aprotinin, 10 μg/ml leupeptin, 20 mM β-glycerophosphate and 2 mM sodium fl uoride). Cell lysates were clarifi ed by centrifugation at 15,000×g for 10 minutes at 4 o C, and lysate protein concentrations were determined with a BCA protein assay reagent kit as described by the manufacturer (Pierce; Rockford, IL). For immunoblotting, immunoprecipitates or whole cell lysates were denatured in Laemmli sample buffer, and resolved by SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose, and immunoblot analysis was performed using appropriate primary antibodies. Immune complexes on nitrocellulose were detected by the ECL-Plus chemiluminescent system (Amersham Pharmacia Biotech, Piscataway, NJ). Fluorescent images were captured using KODAK Image Station 4000R (Carestream Health, Inc., Rochester, NY). Bands were quantifi ed using Kodak Molecular Imaging software, version 4.5.0 (Carestream Health, Inc.).
In vitro Raf-1 kinase activity assay
Raf-1 proteins were specifi cally immunoprecipitated from whole cell lysates using 1 μg monoclonal anti-Raf-1 antibody directed against the carboxy-terminal domain. After incubation DOI: 10.4062/biomolther.2011.19.2.174 for 2 hours at 4 o C, immunoprecipitates were washed three times with lysis buffer, and once with kinase buffer (20 mM Tris, pH 7.4, 20 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl 2 ). Raf-1 kinase activity was measured by phosphorylation of recombinant MEK (Santa Cruz Biotechnology) as previously described (Lee, 2006) . The washed immunoprecipitates were incubated in 40 μl of kinase buffer containing 100 μM ATP, and 1 μg of the recombinant MEK at 30 o C for 30 min. The samples were resolved by SDS-PAGE, transferred to nitrocellulose membrane and probed with a polyclonal anti-phospho-MEK antibody. Detection was accomplished using the ECL-Plus chemiluminescent system and visualized using KODAK Image Station 4000R.
Immunofl uorescence staining
For immunofl uorescence experiments, cells were grown on chamber slides (Nunc), and fi xed in 10% formalin solution for 10 min as described (Ahn et al., 2010) . Samples were blocked with blocking solution (1% BSA, 0.6% Triton X-100 in PBS) for 1 h and incubated with primary antibodies diluted in blocking solution for 16 h at 4 o C. FITC-coupled anti-mouse IgG was used to detect Raf-1 proteins while Texas Red-coupled antirabbit IgG was used to visualize Spry2. Photographs were taken at 1000X magnifi cation through a Zeiss Axio Scope.A1 epifl uorescence microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY).
Co-immunoprecipitation and immunoblot analysis
The cells were transiently transfected with vector expressing FLAG-tagged wt-Raf-1 in combination with that expressing the full-length Spry2 using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. To isolate Spry2-Raf-1 complex, immunoprecipitation was performed on the whole cell lysates using monoclonal anti-FLAG M2, and protein A-agarose beads. For detection of Spry2 proteins coimmunoprecipitated with FLAG-Raf-1, immunoprecipitates were denatured in Laemmli sample buffer, and resolved by 10% SDS-polyacrylamide gel. The proteins were transferred to nitrocellulose, and immunoblot analysis was performed us- www.biomolther.org ing a polyclonal anti-Spry2. Immune complexes on nitrocellulose were detected by enzyme-linked chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ). Fluorescent images were captured using KODAK Image Station 4000R.
RESULTS
Establishment of paclitaxel-resistant cell lines, Ras-NIH 3T3/Mdr
After establishment of paclitaxel-resistant Ras-NIH 3T3/ Mdr cell line by stepwise exposure to increasing concentrations of paclitaxel for 18 weeks, we determined paclitaxel sensitivity in Ras-NIH 3T3/Mdr and compared it with that of its parental Ras-NIH 3T3 cells. The IC 50 for paclitaxel of Ras-NIH 3T3 cells was less than 25 nM (Fig. 1A) . The WST-1 assay demonstrated that Ras-NIH 3T3/Mdr cells become 40-fold (IC 50 : more than 1 μM) more paclitaxel resistant than Ras-NIH 3T3 cells (Fig. 1B) . Additionally, they became resistant to other drugs too therefore a typical MDR phenotype was induced (data not shown).
Drug resistance observed in Ras-NIH 3T3/Mdr is mediated through overexpression of the MDR gene
The loss of the effi cacy of anticancer therapy is correlated predominantly with the overexpression of P-glycoproteins that actively effl ux chemotherapeutic drugs (Gottesman, 2002) . MDR1 and MDR3 that belong to the ATP-binding cassettes (ABC) family are well-known typical transporters. We evaluated the expression of MDR1 and MDR3 of Ras-NIH 3T3 and Ras-NIH 3T3/Mdr cells by RT-PCR analysis. MDR3 as well as MDR-1 mRNA was overexpressed in Ras-NIH 3T3/Mdr cells but not in Ras-NIH 3T3 cells ( Fig. 2A) . We also confi rmed the increased expression of Mdr proteins in Ras-NIH 3T3/Mdr by immunoblotting analysis (Fig. 2B) . Additionally, we examined whether verapamil affects cell proliferation in Ras-NIH 3T3/ Mdr cells. Verapamil, calcium channel blocker, has been reported to inhibit the transport function of P-glycoprotein (Nobili et al., 2006) . Paclitaxel resistance of Ras-NIH 3T3/Mdr cells was completely blocked with the addition of non-cytotoxic concentrations of verapamil (Fig. 2C) , suggesting that the overexpression of MDR mRNA in Ras-NIH 3T3/Mdr cells results in the production of a functional P-glycoprotein.
The role of Raf-1 kinase in acquired multidrug resistance of Ras-NIH 3T3/Mdr cells
One of the reported mechanisms by which of MDR is induced in paclitaxel-resistant cells is the induction by Raf-1 (Davis et al., 2003) . As shown in Fig. 3A , Raf-1 kinase analysis revealed that basal Raf-1 kinase activity was higher in Ras-NIH 3T3/Mdr cells than in Ras-NIH 3T3 cells, suggesting that Raf-1 kinase activity in drug-resistant cells is closely correlated to the development of drug resistance. As shown in Fig. 3B , it was also observed signifi cantly increased phosphorylation of downstream kinase of Raf-1, ERK, in Ras-NIH3T3/Mdr cells. Since the cell death by paclitaxel is associated with apoptosis, we also compared the expression of major apoptosis-related genes, Bcl-2, and cleaved PARP in these cells. However, expression level of all of these genes was not changed between parent and resistant cells (Fig. 3C) .
The change in the interaction between Raf-1 and Spry2 in Ras-NIH 3T3/Mdr cells
Our recent data indicate that Spry2 may regulate Raf-1 kinase activity by acting as a scaffolding protein that brings Raf-1 kinase into close proximity with its direct regulators (Ahn et al., 2010) . Here, we revealed that PDGF-induced Raf-1 activation was inversely correlated with the strength of interaction with Spry2 as monitored by co-immunoprecipitation experiment (Fig. 4A) . Next, the endogenous expression levels of Spry2 were evaluated in both cell lines. The expression level of Spry2 in Ras-NIH 3T3/Mdr cells was much higher than in its parental cells (Fig. 4B) . The Raf-1 association with Spry2 in intact cells was further investigated by immunofl uores- cence colocalization in Ras-NIH 3T3 and Ras-NIH 3T3/Mdr cells (Fig. 4C) . Immunofl uorescence studies revealed Raf-1 proteins was localized to the cytoplasm and nucleus in both cell lines. Spry2 proteins were cytoplasmic with concentrated localization around the nucleus in the perinuclear zone in Ras-NIH 3T3/Mdr cells whereas showing more diffused in the cytoplasm in Ras-NIH 3T3 cells. Merged images of Raf-1 and Spry2 showed colocalization in the cytoplasm of Ras-NIH 3T3 cells. However, the colocalization of Raf-1 and Spry2 was less observed in cytoplasm of Ras-NIH 3T3/Mdr cells due to concentrated localization of Spry2 around the nucleus in the perinuclear zone. In order to further confi rm the change in the interaction of Raf-1 and Spry2, we tested the ability of Raf-1 to interact with Spry2 in Ras-NIH 3T3/Mdr cells and their parental cells expressing FLAG-tagged Raf-1 (Fig. 4D) . As expected, we observed that the interaction level of Raf-1 and Spry2 in Ras-NIH 3T3/Mdr cells were less than that in Ras-NIH 3T3 cells. These observations led to the hypothesis that Raf-1 may be released from negative feedback inhibition by interacting with Spry2.
Eff ect of RNAi targeting Raf-1 on chemosensitivity to paclitaxel in Ras-NIH 3T3/Mdr cells
In order to investigate the hypothesis that Raf-1 kinase plays a positive role in drug resistance, we knocked down the Raf-1 mRNA by shRNA. We fi rst tested the silencing effi ciency of the shRNAs against endogenous Raf-1. Of those tested, shRNA#1 was the most effective in decreasing the expression of Raf-1 (data not shown). Raf-1 shRNA transfection signifi cantly decreased P-glycoprotein expression compared with controls as determined by western blot assay (Fig. 5A) . 
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Next, WST-1 assay was employed to investigate the reversal effect of Raf-1 shRNA transfection on the multidrug resistance of Ras-NIH 3T3/Mdr cells. Fig. 5B shows that Raf-1 knockdown cells were more susceptible to paclitaxel treatment than mock cells. The partial rescue after Raf-1 siRNA transfection could be explained by incomplete knockdown of Raf-1 in the experiment. Actually, our preliminary data showed that 30% of Raf-1 still remained after Raf-1 siRNA transfection due to the incomplete knockdown of siRNA (data not shown). These results support a role for Raf-1 in mediating the drug resistance of Ras-NIH 3T3/Mdr cells.
DISCUSSION
The acquisition of multidrug resistance by cancer cells is correlated predominantly with the overexpression of P-glycoproteins that actively effl ux chemotherapeutic drugs (Gottesman, 2002) . Here, we also identifi ed that verapamil, a specifi c P-glycoprotein effl ux pump inhibitor (Nobili et al., 2006) , completely restored paclitaxel sensitivity in Ras-NIH 3T3/Mdr cells, implying that P-glycoprotein overexpression is the main reason of paclitaxel resistance in Ras-NIH 3T3/Mdr cell line. In addition, our results showed that one of mechanisms by which P-glycoprotein overexpression was induced in Ras-NIH 3T3 cells was Raf-1 kinase activation, indicating that the distal events triggered by Raf-1 activation are the ultimate effectors of the drug resistance phenotype. Conversely, we could not detect differences of expression in apoptosis-related genes, such as bcl-2 and PARP between parental and paclitaxelresistant cell lines Our fi ndings for the role of Raf-1 kinase in drug-resistance are very consistent with other reports, suggesting that Raf-1 signal transduction pathways may be involved in the regulation of several aspects of drug resistance (Weinstein-Oppenheimer et al., 2001; Abrams et al., 2010) . Several studies reported that increased activation of Raf-1 may up-regulate transcription of P-glycoprotein (Cornwell and Smith, 1993; Kim et al., 1996) . In addition, there are several reports showing that modulation of Raf-1 kinase altered susceptibility of breast cancer cells to the chemotherapeutic drugs (Weinstein-Oppenheimer et al., 2001; Davis et al., 2003; Lee et al., 2003) .
Although a correlation between high Raf-1 activity and drug resistance has been suggested in several reports (WeinsteinOppenheimer et al., 2001; Zhong et al., 2001) , the induction mechanism for constitutively active Raf-1 kinase responsible for P-glycoprotein overexpression remains unclear. In contrast to the detailed data collected on the Raf-1 activation process, the mechanism responsible for Raf-1 inactivation after signaling events is much less understood. Possible candidate for the feedback negative regulation of the Raf-1/MAP kinase pathway is the Sprouty (Spry) protein (Yusoff et al., 2002; Sasaki et al., 2003; Ahn et al., 2010) , which was found to be a general inhibitor of receptor tyrosine kinases (Hacohen et al., 1998) . Our study revealed that the expression level of Spry2 in Ras-NIH 3T3/Mdr cells was much higher than in their parental cells. Unexpectedly, however, immunofl uorescence assay showed that colocalization of Raf-1 and Spry2 was less observed in cytoplasm of Ras-NIH 3T3/Mdr cells compared to Ras-NIH 3T3 cells due to concentrated localization of Spry2 around the nucleus in the perinuclear zone. These observations led to the hypothesis that Raf-1 might be released from negative feedback inhibition by interacting with Spry2 in Ras-NIH 3T3/Mdr cells.
Although Raf-1 overexpression correlated with the development of multidrug resistance in Ras-NIH 3T3/Mdr cells, RNAi targeting Raf-1 partially restored chemosensitivity to paclitaxel in Ras-NIH 3T3/Mdr cells. Hyperactivation of Raf-1 kinase may not be suffi cient as an explanation of the mechanism that Ras-NIH 3T3/Mdr cells acquire the multidrug-resistance phenotype after exposure to paclitaxel. Mercer and Pritchard (2003) identifi ed B-Raf rather than Raf-1 as the primary Raf isoform for for activating ERK pathway. Thus, future studies are aimed at elucidating the molecular mechanisms underlying the biological effects of B-Raf on acquired multidrug resistance. This will, in turn, help us understand B-Raf modulation through negative feedback regulation of Sprouty by paclitaxel. 
